Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine vs MGCD0103 vs azacitidine + MGCD0103 in elderly patients with newly diagnosed AML or higher-risk MDS
2007-005584-10Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Single-agent azacitidine, Single-agent MGCD0103 and Azacitidine + MGCD0103 (3 arms). Primary endpoints: Overall response rate and Complete remission or partial remission. Started Jan 2008; status: terminated.
02
Drugs
azacitidinemocetinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2007-005584-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005584-10.